What are the side effects of Omarigliptin?

Omarigliptin (Omarigliptin) is a potent inhibitor of DPP-4, highly selective for other tested proteases (IC50>67μmol/L), and has weak ion channel activity. Ologliptin rapidly and competitively binds to the active site of DPP-4. This process is reversible and highly selective, thus leading to increased insulin levels and decreased glucagon levels under hyperglycemic conditions.

In clinical trials of ologliptin, common adverse reactions include hypoglycemia, constipation, etc. There are no case reports of death, serious adverse events or hypoglycemia. Be cautious of hypoglycemia during use of ologliptin. In particular, the risk of hypoglycemia is increased when coadministered with insulin preparations or sulfonylureas, so a dose reduction of these drugs should be considered. Careful observation of the patient's blood glucose levels and other conditions is required when ologliptin is used concomitantly with drugs that enhance the hypoglycemic effect. Careful observation of the patient's blood glucose levels and other conditions is required when ologliptin is coadministered with drugs that reduce hypoglycemic effects.

Patients with severe renal impairment and end-stage renal failure requiring hemodialysis or peritoneal dialysis. These patients should have appropriate dose adjustments and blood levels of this drug may be increased. At the same time, considering the therapeutic benefits of breastfeeding, migration into milk has been reported in animal studies (rats), and consideration should be given to continuing or discontinuing breastfeeding.

The original drug Ologliptin is not marketed in the country and is therefore not included in medical insurance. The price of each box of generic Ologliptin drugs currently on the market overseas may be more than more than 1,000 yuan (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.